TW202126306A - 嗜酸性球性病症之治療 - Google Patents

嗜酸性球性病症之治療 Download PDF

Info

Publication number
TW202126306A
TW202126306A TW109134501A TW109134501A TW202126306A TW 202126306 A TW202126306 A TW 202126306A TW 109134501 A TW109134501 A TW 109134501A TW 109134501 A TW109134501 A TW 109134501A TW 202126306 A TW202126306 A TW 202126306A
Authority
TW
Taiwan
Prior art keywords
eosinophilic
compound
pharmaceutically acceptable
administration
eosinophils
Prior art date
Application number
TW109134501A
Other languages
English (en)
Chinese (zh)
Inventor
布倫頓 馬爾
Original Assignee
美商纜圖藥品公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商纜圖藥品公司 filed Critical 美商纜圖藥品公司
Publication of TW202126306A publication Critical patent/TW202126306A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW109134501A 2019-10-04 2020-10-05 嗜酸性球性病症之治療 TW202126306A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962910931P 2019-10-04 2019-10-04
US62/910,931 2019-10-04

Publications (1)

Publication Number Publication Date
TW202126306A true TW202126306A (zh) 2021-07-16

Family

ID=73030210

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109134501A TW202126306A (zh) 2019-10-04 2020-10-05 嗜酸性球性病症之治療

Country Status (6)

Country Link
US (1) US20240075041A1 (cg-RX-API-DMAC7.html)
EP (1) EP4041244B1 (cg-RX-API-DMAC7.html)
JP (2) JP2022551105A (cg-RX-API-DMAC7.html)
CN (1) CN114746096A (cg-RX-API-DMAC7.html)
TW (1) TW202126306A (cg-RX-API-DMAC7.html)
WO (1) WO2021067917A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX365614B (es) 2013-10-17 2019-06-07 Blueprint Medicines Corp Composiciones utiles para tratar trastornos relacionados con kit.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2593319T3 (es) * 2005-05-02 2016-12-07 Novartis Ag Derivados de pirimidilaminobenzamida para síndrome hipereosinofílico
JP2009515978A (ja) * 2005-11-14 2009-04-16 バイエル ヘルスケア エルエルシー Kit阻害剤に対する獲得耐性を伴う癌の治療
ES2429107T3 (es) * 2007-01-19 2013-11-13 Bayer Healthcare Llc Tratamiento de cánceres con una resistencia adquirida a los agentes inhibidores de KIT
ES2573831T3 (es) * 2011-07-27 2016-06-10 Ab Science Derivados de oxazol y tiazol como inhibidores selectivos de la proteína quinasa (C-kit)
EP2768480A1 (en) * 2011-10-21 2014-08-27 Rigel Pharmaceuticals, Inc. Method and device for administering xinafoate salt of n4-(2,2-difluoro-4h-benzo [1,4]oxazin-3-one) -6-yl]-5-fluoro-n2- [3- (methylaminocarbonylmethyleneoxy) phenyl]2,4-pyrimidinediamine
KR101652229B1 (ko) * 2012-06-07 2016-08-30 데시페라 파마슈티칼스, 엘엘씨. 증식성 질환의 치료를 위한 키나제 저해제로서 유용한 다이하이드로나프타이리딘 및 관련 화합물
MX365614B (es) * 2013-10-17 2019-06-07 Blueprint Medicines Corp Composiciones utiles para tratar trastornos relacionados con kit.
CN109970745B (zh) * 2018-04-16 2020-12-08 深圳市塔吉瑞生物医药有限公司 取代的吡咯并三嗪类化合物及其药物组合物及其用途

Also Published As

Publication number Publication date
JP2022551105A (ja) 2022-12-07
EP4041244B1 (en) 2026-07-15
EP4041244A1 (en) 2022-08-17
JP2025169361A (ja) 2025-11-12
WO2021067917A1 (en) 2021-04-08
US20240075041A1 (en) 2024-03-07
CN114746096A (zh) 2022-07-12

Similar Documents

Publication Publication Date Title
EP4385571B1 (en) A lysyl oxidase-like 2 inhibitor for use in treating primary myelofibrosis
US10806735B2 (en) Use of neutrophil elastase inhibitors in liver disease
BRPI0616324A2 (pt) formulaÇço de cÁpsula de pirfenidona e excipientes farmaceuticamente aceitÁveis
JP2017526713A (ja) 線維症を処置するためのセニクリビロック併用療法
JP2015511632A (ja) メラノーマの治療におけるraf阻害剤およびmek阻害剤の投与
JP7640033B2 (ja) ピリド[1,2-a]ピリミジノン類似体の使用
JP2012077084A (ja) 腎疾患の治療におけるモノおよびジカルボン酸のアミドの使用
JP2025169361A (ja) アバプリチニブでの好酸球性障害の治療
CN115038447A (zh) 用于治疗癌症的组合疗法
TWI828155B (zh) 吡咯并嘧啶類化合物的用途
TW202341973A (zh) 治療性化合物、調配物、及其用途
CN113329749A (zh) 用于治疗葡萄膜黑色素瘤的联合疗法
TW202241415A (zh) 通路調節劑、含其的醫藥組成物、其用途和採用其的治療方法
CN111419800B (zh) 用于治疗红斑狼疮的药物制剂及其制备方法
JP2023501397A (ja) 肥満細胞疾患および好酸球性障害の治療
US20230398123A1 (en) Methods to treat inflammatory bowel disease
KR20150003786A (ko) Pi3k 저해제 및 mek 저해제를 이용한 암 치료 방법
TWI843217B (zh) 一種藥物組合及其應用
JP2020536846A (ja) Fgfr選択的チロシンキナーゼ阻害剤を含む医薬組成物
HK40086505A (en) Methods to treat inflammatory bowel disease
EP2384752A1 (de) Kombinationspräparat umfassend einen Phosphodiesterasehemmer und einen COX-Inhibitor zur Behandlung von Krebs
CN115120732A (zh) 一种喹唑啉化合物的药物组合物及其制备方法
KR20100058662A (ko) 개에게서 림프종을 치료하기 위한 이다루비신
KR102739607B1 (ko) 카바메이트 화합물을 포함하는 조현병의 예방, 경감 또는 치료용 배합물
CN115120596A (zh) 一种喹唑啉化合物及药物组合物的应用